Publication | Closed Access

High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome

Cell TherapyMedicinePoor Clinical OutcomeStem Cell MobilizationHematologyImmunologyStem Cell TransplantationStem Cell ResearchStem-cell TherapyCell TransplantationStem CellsCell BiologyVivo PurgingCd34-positive CellsHealth Sciences